Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.80
ETRM's Cash to Debt is ranked lower than
66% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. ETRM: 0.80 )
Ranked among companies with meaningful Cash to Debt only.
ETRM' s Cash to Debt Range Over the Past 10 Years
Min: 0.8  Med: 4.39 Max: No Debt
Current: 0.8
Equity to Asset -0.24
ETRM's Equity to Asset is ranked lower than
95% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. ETRM: -0.24 )
Ranked among companies with meaningful Equity to Asset only.
ETRM' s Equity to Asset Range Over the Past 10 Years
Min: -0.24  Med: 0.32 Max: 0.62
Current: -0.24
-0.24
0.62
F-Score: 2
Z-Score: -31.18
M-Score: 0.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -4948.48
ETRM's Operating margin (%) is ranked lower than
98% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. ETRM: -4948.48 )
Ranked among companies with meaningful Operating margin (%) only.
ETRM' s Operating margin (%) Range Over the Past 10 Years
Min: -7250.48  Med: -7250.48 Max: -4948.48
Current: -4948.48
-7250.48
-4948.48
Net-margin (%) -4157.75
ETRM's Net-margin (%) is ranked lower than
98% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 1.24 vs. ETRM: -4157.75 )
Ranked among companies with meaningful Net-margin (%) only.
ETRM' s Net-margin (%) Range Over the Past 10 Years
Min: -7543.41  Med: -7543.41 Max: -4157.75
Current: -4157.75
-7543.41
-4157.75
ROE (%) -1461.83
ETRM's ROE (%) is ranked lower than
99% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. ETRM: -1461.83 )
Ranked among companies with meaningful ROE (%) only.
ETRM' s ROE (%) Range Over the Past 10 Years
Min: -1718.77  Med: -140.32 Max: -77.38
Current: -1461.83
-1718.77
-77.38
ROA (%) -181.31
ETRM's ROA (%) is ranked lower than
95% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 0.05 vs. ETRM: -181.31 )
Ranked among companies with meaningful ROA (%) only.
ETRM' s ROA (%) Range Over the Past 10 Years
Min: -182.68  Med: -83.42 Max: -60.09
Current: -181.31
-182.68
-60.09
ROC (Joel Greenblatt) (%) -6199.88
ETRM's ROC (Joel Greenblatt) (%) is ranked lower than
94% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 4.17 vs. ETRM: -6199.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ETRM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -6199.88  Med: -2401.78 Max: -578.16
Current: -6199.88
-6199.88
-578.16
EBITDA Growth (3Y)(%) -23.20
ETRM's EBITDA Growth (3Y)(%) is ranked lower than
86% of the 192 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. ETRM: -23.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ETRM' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -59.35 Max: -23.2
Current: -23.2
EPS Growth (3Y)(%) -23.50
ETRM's EPS Growth (3Y)(%) is ranked lower than
82% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. ETRM: -23.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ETRM' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -69.1  Med: -56.1 Max: -0.8
Current: -23.5
-69.1
-0.8
» ETRM's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-16)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2014

ETRM Guru Trades in Q2 2014

Chuck Royce 1,060,000 sh (-17.51%)
» More
Q3 2014

ETRM Guru Trades in Q3 2014

Chuck Royce 648,600 sh (-38.81%)
» More
Q4 2014

ETRM Guru Trades in Q4 2014

Chuck Royce Sold Out
» More
Q2 2016

ETRM Guru Trades in Q2 2016

Jim Simons 250,538 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with ETRM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:OTCPK:EQUR, OTCPK:VYCO, AMEX:NSPR, NAS:AHPI, OTCPK:ACAR, OTCPK:ECGI, NAS:ESMC, OTCPK:VRSEF, NAS:PHMD, OTCPK:BIAD, OTCPK:PYNGF, OTCPK:ACXA, OTCPK:AIRW, OTCPK:ZYXI, NAS:DYNT, OTCPK:GIDYL, OTCPK:SMLR, OTCPK:AROSF, NAS:MDGS, OTCPK:PETV » details
Traded in other countries:BY8A.Germany,
EnteroMedics Inc is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders.

EnteroMedics Inc was incorporated in Minnesota on December 19, 2002 and later reincorporated in Delaware on July 22, 2004. It is a medical device company with approvals to commercially launch its product, the Maestro Rechargeable System, in the United States, Australia, the European Economic Area and other countries that recognize the European CE Mark. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company's proprietary neuroblocking technology, VBLOC therapy, is designed to intermittently block the vagus nerve using high frequency, low energy, electrical impulses. The Company's initial product, the Maestro Rechargeable System uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company has regulatory approval to sell its product in Australia, the European Economic Area and other countries that recognize the European CE Mark and do not have any other source of revenue. The Company relies on third-party manufacturers and suppliers for the production of its Maestro Rechargeable System. The Company competes in the market for obesity treatment with surgical obesity procedures and various devices used to implement neurostimulation and gastric stimulation systems. The Company also competes against the manufacturers of pharmaceuticals that are directed at treating obesity. The Company's opeartors include: Roche, GlaxoSmithKline, Arena Pharmaceuticals, Inc., VIVUS, Inc. and Orexigen Therapeutics, Inc. The Company also competes with several private early-stage companies developing neurostimulation devices for application to the gastric region and related nerves for the treatment of obesity. The Company has 32 national stage patent applications, including applications in Australia, China, India, Europe and Japan, one granted Chinese application and one granted application in Japan. In addition, the Company is the exclusive licensee to three U.S. patents owned by the Mayo Foundation for Medical Education and Research, which are unrelated to the Company's VBLOC therapy. Maestro Rechargeable System is regulated by the FDA as a medical device under the Federal Food, Drug, and Cosmetic Act (FFDCA) and the regulations promulgated under the FFDCA.

Ratios

vs
industry
vs
history
P/S 2.14
ETRM's P/S is ranked higher than
64% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 3.23 vs. ETRM: 2.14 )
Ranked among companies with meaningful P/S only.
ETRM' s P/S Range Over the Past 10 Years
Min: 1.71  Med: 256.85 Max: 1106.25
Current: 2.14
1.71
1106.25
Current Ratio 1.37
ETRM's Current Ratio is ranked lower than
81% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.56 vs. ETRM: 1.37 )
Ranked among companies with meaningful Current Ratio only.
ETRM' s Current Ratio Range Over the Past 10 Years
Min: 1.01  Med: 3.27 Max: 9.46
Current: 1.37
1.01
9.46
Quick Ratio 1.18
ETRM's Quick Ratio is ranked lower than
73% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 1.94 vs. ETRM: 1.18 )
Ranked among companies with meaningful Quick Ratio only.
ETRM' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 3.13 Max: 9.46
Current: 1.18
0.81
9.46
Days Inventory 2.00
ETRM's Days Inventory is ranked higher than
98% of the 280 Companies
in the Global Medical Devices industry.

( Industry Median: 132.35 vs. ETRM: 2.00 )
Ranked among companies with meaningful Days Inventory only.
ETRM' s Days Inventory Range Over the Past 10 Years
Min: 2  Med: 1840.73 Max: 1840.73
Current: 2
2
1840.73
Days Sales Outstanding 119.06
ETRM's Days Sales Outstanding is ranked lower than
81% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 68.07 vs. ETRM: 119.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
ETRM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.03  Med: 61.03 Max: 119.06
Current: 119.06
61.03
119.06
Days Payable 450.88
ETRM's Days Payable is ranked higher than
97% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 57.81 vs. ETRM: 450.88 )
Ranked among companies with meaningful Days Payable only.
ETRM' s Days Payable Range Over the Past 10 Years
Min: 450.88  Med: 536.49 Max: 536.49
Current: 450.88
450.88
536.49

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -23.70
ETRM's 3-Year Average Share Buyback Ratio is ranked lower than
83% of the 211 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. ETRM: -23.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ETRM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -356.3  Med: -124.2 Max: -23.7
Current: -23.7
-356.3
-23.7

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.01
ETRM's Price/Median PS Value is ranked higher than
100% of the 253 Companies
in the Global Medical Devices industry.

( Industry Median: 1.06 vs. ETRM: 0.01 )
Ranked among companies with meaningful Price/Median PS Value only.
ETRM' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 1.07 Max: 2.64
Current: 0.01
0.01
2.64
Earnings Yield (Greenblatt) (%) -307.12
ETRM's Earnings Yield (Greenblatt) (%) is ranked lower than
99% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. ETRM: -307.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ETRM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -2018.65  Med: 474.55 Max: 2321.2
Current: -307.12
-2018.65
2321.2

More Statistics

Revenue (TTM) (Mil) $0.56
EPS (TTM) $ -3.00
Beta2.54
Short Percentage of Float5.94%
52-Week Range $0.11 - 4.95
Shares Outstanding (Mil)27.29

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 1 3 6
EPS ($) -2.30 -1.14 -0.85
EPS w/o NRI ($) -2.30 -1.14 -0.85
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ETRM

Headlines

Articles On GuruFocus.com
Kevin Douglas Bets on EnteroMedics; Popeyes and AMERCO Top Estimates May 28 2015 
Canaccord Genuity Remains Bullish on EnteroMedics Following Q4 Earnings Feb 19 2015 
Analysts Are Bullish On EnteroMedics Following FDA Approval Of Obesity Treatment Jan 16 2015 
EnteroMedics Inc. Reports Operating Results (10-K) Mar 07 2011 
EnteroMedics Inc. Reports Operating Results (10-Q) Nov 08 2010 
EnteroMedics Inc. Reports Operating Results (10-Q) Aug 06 2010 
EnteroMedics Inc. Reports Operating Results (10-Q) May 07 2010 
EnteroMedics Inc. Reports Operating Results (10-Q) Nov 16 2009 
EnteroMedics Inc. Reports Operating Results (10-Q) Aug 07 2009 
EnteroMedics Inc. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
ENTEROMEDICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Sep 27 2016
EnteroMedics Announces Appointment of Dan Gladney as Chairman of the Board of Directors Sep 27 2016
7:03 am EnteroMedics names President and CEO Dan Gladney to replace co-founder Dr. Mark Knudson, who... Sep 27 2016
EnteroMedics Announces Appointment of Dan Gladney as Chairman of the Board of Directors Sep 27 2016
EnteroMedics to Present at the Ladenburg Thalmann Healthcare Conference Sep 21 2016
ENTEROMEDICS INC Files SEC form 8-K, Change in Directors or Principal Officers Sep 20 2016
EnteroMedics Announces Receipt of Notice of Intention to Grant European Patent Covering Safety... Sep 19 2016
EnteroMedics Announces Receipt of Notice of Intention to Grant European Patent Covering Safety... Sep 19 2016
vBloc Institute Demonstrates Positive Clinical Success in Patients Struggling with Weight Loss as... Sep 13 2016
vBloc Institute Demonstrates Positive Clinical Success in Patients Struggling with Weight Loss as... Sep 13 2016
ENTEROMEDICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Sep 12 2016
EnteroMedics Announces Appointment of Scott Youngstrom as Chief Financial Officer and Chief... Sep 07 2016
EnteroMedics Announces Appointment of Scott Youngstrom as Chief Financial Officer and Chief... Sep 07 2016
ENTEROMEDICS INC Financials Aug 20 2016
ENTEROMEDICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events,... Aug 17 2016
EnteroMedics Announces Appointment of Gary Blackford to its Board of Directors Aug 17 2016
EnteroMedics Announces Appointment of Gary Blackford to its Board of Directors Aug 17 2016
EnteroMedics Announces Publication of 24 Month ReCharge Clinical Study Data in Obesity Surgery Aug 15 2016
EnteroMedics Announces Publication of 24 Month ReCharge Clinical Study Data in Obesity Surgery Aug 15 2016
ENTEROMEDICS INC Files SEC form 10-Q, Quarterly Report Aug 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)